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218 The Journal of Thoracic and CardioObjective: Severe primary graft dysfunction occurs in 10% to 20% of lung trans-
plant recipients and is the leading cause of early death after lung transplantation. We
hypothesized that altering the content of the initial reperfusate and maintaining a
low reperfusion pressure after surgical implantation would lead to a low incidence
of primary graft dysfunction.
Methods: We analyzed the records of all patients who underwent lung transplantation
at our institution from March 1, 2000, to August 30, 2004. The modified reperfusion
technique involved the insertion of a catheter into the main or individual pulmonary
artery after implantation. The recipient blood was depleted of leukocytes; supple-
mented with nitroglycerin; adjusted for pH and calcium level; enriched with aspar-
tate, glutamate, and dextrose; and then administered into the pulmonary arteries of
the newly transplanted lung(s) for the first 10 minutes of reperfusion. Severe
primary graft dysfunction was defined as a PaO2/inspired oxygen fraction of less
than 150 with diffuse infiltrate on the radiograph in absence of other causes.
Results: During this interval, 100 patients underwent lung transplantation with the
modified reperfusion technique. Forty-two patients underwent single-lung transplanta-
tion, of which 5 patients required cardiopulmonary bypass for the procedure. Fifty-eight
patients underwent double-lung transplantation; all double-lung transplantation pro-
cedures were performed with patients on cardiopulmonary bypass. There were no
technical complications associated with the modified reperfusion. The mean PaO2/
inspired oxygen fraction at 6 hours in this cohort was 252  123 mm Hg. The
median number of days on the ventilator was 2. More importantly, the incidence of
severe primary graft dysfunction in this cohort was 2.0%. The early survival (30-day
or in-hospital mortality) of this group of patients was 97%.
Conclusions: The technique of modified reperfusion in human lung transplantation
is associated with a low incidence of severe primary graft dysfunction and favorable
short-term outcomes.
Lung transplantation is a well-established treatment option for patients withend-stage lung diseases. Approximately 1500 lung transplantations are per-formed annually, and more than 17,000 have been performed worldwide though
2004.1 Despite this breadth of experience and improved donor management and pres-
ervation techniques, ischemia-reperfusion injury or primary graft dysfunction (PGD)
remains a significant cause of early morbidity and mortality after lung transplantation.
Although PGD refers to a spectrum of lung allograft injuries after transplantation, its
most severe form is estimated to occur in 10% to 20% of lung transplant recipients with
an associated mortality of 40%.2,3 The syndrome generally occurs within the first 72
hours after transplantation and is characterized by nonspecific alveolar damage, lung
edema, poor compliance, and hypoxemia. The treatment for PGD remains primarily
supportive, and in addition to the high mortality associated with this phenomenon,
vascular Surgery ● January 2006
Schnickel et al Cardiothoracic Transplantation
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left with residual impaired lung function.3 Severe PGD can
also be associated with an increased risk of acute rejection
and late bronchiolitis obliterans syndrome.4
Recipient leukocytes are known to play an integral role
in the development of PGD in lung transplantation. Exper-
imental studies have shown that neutrophils and T lympho-
cytes infiltrate the lung allografts and contribute to graft
injury through a variety of mechanisms, including the re-
lease of toxic oxygen metabolites, inflammatory cytokines,
and other mediators.5,6 In addition to recipient leukocytes,
the noncellular composition of the reperfusate also contrib-
utes to the process of ischemia-reperfusion injury by exacer-
bating cellular edema and death.7 Modification of the initial
reperfusate after regional myocardial ischemia has been
associated with improved functional recovery.7 Moreover,
application of this technique in experimental models of lung
transplantation has resulted in improved allograft function
and oxygenation.8,9 We have previously reported on our
experience with modified reperfusion in a cohort of 23
patients.10 The purpose of this study was to assess the short-
and medium-term outcome of modified reperfusion in a
group of 100 consecutive lung transplant recipients.
Materials and Methods
Study Population
We analyzed the records of all patients who underwent lung
transplantation at our institution from March 1, 2000, to August
30, 2004. During this interval, 100 patients had received modified
reperfusion with their lung transplantation, and they are the sub-
jects of this study. One patient during this time period did not
receive modified reperfusion because of the decision of the sur-
geon. The first 12 lung transplant recipients included in this cohort
were enrolled in a previously reported study.10 This study was
approved by the University of California, Los Angeles Institutional
Review Board.
Allograft Harvest and Implantation
Donor lungs were harvested by using the previously described
technique.11 Donor lung pulmonary artery beds were pretreated
with 500 g of prostaglandin E1, followed by administration of 4
L of either modified Euro-Collins solution (the first 41 recipients;
Baxter Healthcare Corp, Deerfield, Ill) or low-potassium dextran
solution (the last 59 recipients; Perfadex; Vitrolife, Uppsala, Swe-
den) under a perfusion pressure less than 20 mm Hg. All allografts
were procured in inflation with a tidal volume of approximately
Abbreviations and Acronyms
CPB  cardiopulmonary bypass
FIO2  inspired oxygen fraction
ICU  intensive care unit
PGD primary graft dysfunction10 mL/kg and with a inspired oxygen fraction (FIO2) of 1.0. Meth-
The Journal of Thoraciylprednisolone (7 mg/kg) was given to all recipients before sur-
gery. Allograft implantation was performed according to a previ-
ously described technique.12 All double lung transplantations were
performed on cardiopulmonary bypass (CPB). Allograft ischemia
time for this group of patients refers to the time until both lung
allografts were reperfused. Aprotinin is used in all patients who
undergo lung transplantation on CPB.
Modified Reperfusion
After implantation of a right or left single-lung allograft (off CPB),
a cannula was inserted into the right atrium or descending thoracic
aorta, respectively.10 The recipient blood was removed, depleted
of leukocytes via leukofilter (LeukoGuard BC1B for the first 6
recipients and then LeukoGuard LG6B; Pall Biomedical Products,
East Hills, NY), and then mixed with the modified reperfusion
solution in a 4:1 ratio via a roller pump. The efficacy of leukofilters
in removal of leukocytes has previously been demonstrated in both
experimental and clinical studies.13,14 The precise content of the
modified reperfusion solution has previously been described.10
The modified reperfusate was then administered through a cannula
that had been inserted into the clamped pulmonary artery via the
suture line. The modified reperfusion pressure was continuously
monitored and maintained at a pressure less than 20 mm Hg. The
flow varied from 200 to 500 mL/min per lung allograft. During
reperfusion, patients were ventilated in a pressure-controlled mode
with tidal volume of approximately 8 mL/kg on room air and with
a positive end-expiratory pressure of 5 mm Hg. The effluent during
the first 3 minutes of reperfusion was collected by a cell-saving
device (in patients undergoing transplantation without CPB). After
the first 3 minutes of reperfusion and after adequate deairing of the
allograft, the left atrial clamp was removed to allow return of the
leukocyte-depleted blood into the recipient’s left atrium. After 3
minutes, the modified reperfusion solution was switched to leuko-
cyte-depleted blood, which was continued for an additional 7
minutes. Activated clotting time was maintained over 200 seconds
during the reperfusion phase.
In patients undergoing single-lung transplantation on CPB, the
pump blood was used to reperfuse the allograft after leukofiltration
and mixing with the modified reperfusate solution. In patients under-
going double-lung transplantation on CPB, the modified reperfusate
was administered into the main pulmonary artery in a similar
fashion at a pressure less than 20 mm Hg. After 10 minutes of
modified reperfusion, the removal of the pulmonary artery clamp or
weaning off CPB was performed according to usual protocol.
Postoperative Care
All patients were mechanically ventilated in a pressure-controlled
mode with settings adjusted to maintain PaO2 greater than 80 mm
Hg. Positive end-expiratory pressures of 3 to 10 mm Hg were used
to optimize oxygenation and hemodynamics. The immunosuppres-
sion regimen initially consisted of induction with equine antithy-
mocyte globulin (n  5; ATGam; Pharmacia, Peapack, NJ), fol-
lowed by cyclosporine, azathioprine, and prednisone. The regimen
was changed in January 2001 and has subsequently consisted of
induction therapy with rabbit anti-thymocyte globulin (Thymo-
globulin; SangStat, Fremont, Calif), followed by tacrolimus, my-
cophenolate mofetil, and prednisone. The antithymocyte globulin
was administered after surgery. Routine transbronchial lung biop-
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24, and 52. Clinically based procedures were based on decrements
in spirometric function or radiographic infiltrate or on decreased
pulse oximetry.
Definition of Terms
Severe PGD was defined as PaO2/FIO2 less than 150 at 48 hours
after transplantation with radiographic evidence of pulmonary
edema in mechanically ventilated patients, in the absence of other
potential causes. The PaO2 value and chest radiograph closest to 6
and 48 hours after arrival in the intensive care unit (ICU) were
used for data collection for this study. Acute cellular rejection was
diagnosed by transbronchial lung biopsy and graded according to
the International Society for Heart and Lung Transplantation
guidelines: grade 0, no rejection; grade A1, minimal; grade A2,
mild; grade A3, moderate; and grade A4, severe. Early deaths were
defined as deaths within 30 days of the operation or during the
same hospitalization period. All data measurements are presented
as the mean  SD, unless otherwise specified.
Results
Perioperative Characteristics
The recipient diagnoses were obstructive lung disease (n
45), restrictive lung disease (n  42), pulmonary vascular
disease (n  5), and septic lung disease (n  8). The mean
age of recipients was 57  9 years. The most recently
available recipient mean pulmonary artery pressure preced-
ing the transplantation procedure was 38  8 mm Hg.
During this study period, 69 recipients received lung allo-
grafts from donors who met extended donor criteria. The
lungs were classified as extended donor lungs for the pres-
ence of radiographic infiltrate in the donor lung (n  61),
donor age older than 55 years (n  8), donor PaO2/FIO2 less
than 300, an FIO2 of 1.0 (n  5), the presence of purulent
secretions (n  28), and a smoking history greater than 20
pack-years (n  7). Several donors met multiple criteria.
Forty-two patients underwent single-lung transplanta-
tion, of which 5 patients required CPB for the procedure.
Fifty-eight patients underwent double-lung transplantation; all
double-lung transplantations were performed on CPB, with a
mean bypass time of 191  35 minutes. During this interval,
21 patients underwent a concomitant cardiac procedure at the
time of transplantation. These operations included mitral
valve repair (n 1), tricuspid valve repair (n 4), tricuspid
and pulmonic valve repair (n  1), coronary artery bypass
graft (n  2), and patent foramen ovale closure (n  13).
The mean allograft ischemia time for all transplantations
was 310  63 minutes. There were no pulmonary artery
injuries, and there was no postoperative bleeding related to
the modified reperfusion technique.
Postoperative Outcome
The early postoperative characteristics of this cohort of
patients are shown in Table 1. There were no intraoperative
deaths. The mean PaO2/FIO2 at 6 hours after transplantation
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patients had PaO2/FIO2 ratios of less than 150. Thirteen of
these patients received donor lungs with infiltrates (due to
atelectasis, contusion, or pneumonia), and postoperative
chest radiographs (on arrival in the ICU) demonstrated the
persistence of similar infiltrates. One patient had hyperacute
rejection, as demonstrated by donor-specific positive cross-
matching and consistent histologic findings. Another patient
had a PaO2/FIO2 ratio less than 150 with a clear radiograph.
Finally, 3 patients had a PaO2/FIO2 ratio less than 150 with
diffuse radiographic infiltrate at 6 hours. A factor that may
have contributed to the hypoxemia in this cohort is the
relatively high rate of CPB use (63 of 100) and the associ-
ated early lung edema.
The mean PaO2/FIO2 at 48 hours after transplantation was
301  80 mm Hg (n  50 for the group that was mechan-
ically ventilated at 48 hours). At 48 hours after ICU arrival,
3 patients had PaO2/FIO2 ratios less than 150. One patient
had hyperacute rejection, as noted previously. Two patients
had a diagnosis of severe PGD.
In this group of 100 patients, the median number of days
on the ventilator was 2, the median number of days in the
ICU was 4, and the median length of hospital stay was 14
days. In a previous report, acute renal failure developed in
2 patients as a result of hemolysis.10 This was possibly due
to high flows through the leukocyte filter. The filters were
subsequently changed to high-flow leukocyte filters, with no
subsequent episodes of hemolysis.
Two (2.0%) patients from this cohort met the criteria for
severe PGD at 48 hours. Both of these patients had the
diagnosis of pulmonary arterial hypertension and had un-
dergone double-lung transplantation. One of these patients
had had a prior sternotomy and intracardiac repair; she
required femoral artery and vein cannulation and prolonged
CPB for lung transplantation and redo tricuspid valve re-
pair. This patient had a single episode of acute rejection
during the first posttransplantation year. The second patient
had also required tricuspid valve repair and double lung
TABLE 1. Early postoperative characteristics
Variable Data
PaO2/FIO2 at 6 h 252  123
PaO2/FIO2 at 48 h 301  80
Days on ventilator, median (range) 2 (1-202)
Days in ICU, median (range) 4 (2-202)
Length of stay, d, median (range) 14 (6-277)
Incidence of severe PGD (at 48 h) 2.0%
Incidence of acute rejection 0.23 0.47
Early survival 97%
One-year survival 91%
FIO2, Fraction of inspired oxygen; ICU, intensive care unit; PGD, primary
graft dysfunction. Data are mean  SD unless otherwise noted.transplantation. She has had multiple episodes of A2 or
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nosed with bronchiolitis obliterans syndrome (stage 3) at
2 years after transplantation.
The incidence of airway complications requiring inter-
vention during the first posttransplantation year was 0%.
The incidence of acute rejection (grade A2 or higher) during
the first year after transplantation was 0.23  0.47 episodes
per patient-year. There were no significant differences in
any of the end points when they were stratified by preser-
vation solution (data not shown). There were 3 early deaths
in this cohort due to multisystem organ failure (postopera-
tive day 17), sepsis (postoperative day 202), and drug over-
dose in an outpatient (postoperative day 24). The early
survival of this group of patients was 97%, with a 1-year
actuarial survival of 91%.
Discussion
The findings of this study demonstrate that modifying the
initial reperfusate by leukodepletion and altering the com-
position of the solution can be performed safely in human
lung transplantation. Moreover, this technique is associated
with a low incidence of severe PGD and with favorable
early and 1-year outcomes.
PGD in lung transplantation is a complex multifactorial
process that involves participation of innate and adaptive im-
mune systems, complement cascade, reactive oxygen species,
and coagulation factors. Given the complexity of this pro-
cess, it is not surprising that therapies directed at single
pathogenic factors might prove ineffective. The described
technique allows control of both the content and the condi-
tions of the initial reperfusion after surgical implantation.
The importance of controlling the content of the reperfusate
after a period of ischemia has been substantiated in several
experimental and clinical studies.7,9,15,16 Recipient leuko-
cytes and, specifically, neutrophils and T lymphocytes can
mediate ischemia reperfusion injury through a variety of
mechanisms, such as release of toxic oxygen metabolites,
elaboration of elastases and proteases, production of inflam-
matory cytokines, and neutrophil aggregation, thus causing
plugging of capillaries and no-reflow phenomena.5,6,17-19
Removal of leukocytes from the reperfusate has been shown
to improve cardiac allograft histologic characteristics in a
clinical study.20 Thus, it is possible that leukofiltration may
account for at least part of the beneficial effects of modified
reperfusion in this study. In addition to leukocytes, the
acellular composition of the reperfusate is also important in
mediating the severity of the graft injury.7 The composition
of the reperfusate in this study was based on theoretical
grounds, with the goals of neutralizing intracellular and
extracellular acidosis, minimizing tissue edema, enriching
the cellular energy stores by providing the substrates, min-
imizing calcium-induced cellular damage, and ensuring ho-
mogenous delivery.
The Journal of ThoraciIn addition to controlling the content of the reperfusate,
the condition of the reperfusion is also critical in determin-
ing the severity of graft injury. Experimental studies have
demonstrated that maintaining the reperfusion pressure at
less than 20 mm Hg can reduce pulmonary edema and improve
allograft function.21 An integral part of the described reperfu-
sion technique is to control the reperfusion pressure at less
than 20 mm Hg for the first 10 minutes of reperfusion. On
the basis of this study, we cannot decipher which compo-
nent of modified reperfusion technique (leukofiltration vs
modification of the acellular components vs controlling the
pressure) is the dominant factor in mediating the beneficial
effects of this technique.
A limitation of this study is the lack of a control group;
the absence of a contemporaneous cohort does not allow
direct comparison of this approach. The technique of mod-
ified reperfusion is not without its limitations. To perform
modified reperfusion, as described, requires an additional
10 minutes of operative time and increased CPB time for
transplantations performed with patients on bypass. For single-
lung transplantations, this technique requires an additional
cannulation site and the increased risk with which it is
associated. There is also an increased risk of bleeding sec-
ondary to the anticoagulation the technique requires and the
risk of thrombocytopenia, although our early experience
had not demonstrated this to be a problem.10 Because this
technique largely relies on the removal of leukocytes from
the reperfused blood, there may also be a heightened risk of
infection. Moreover, the use of modified reperfusion does
require additional costs. Finally, this technique does not
eliminate the risk of PGD; patients with pulmonary arterial
hypertension who are at high risk of PGD may experience
this complication despite modified reperfusion (2 of 5 pa-
tient in this cohort).
Given the scarcity of “ideal” donor lungs, many trans-
plantation centers have expanded the criteria for donor lung
acceptance, with favorable short- and medium-term out-
comes.22,23 A major concern regarding the use of “non-
ideal” donor lungs is the risk of severe PGD. Strategies such
as modified reperfusion that may decrease the risk of PGD
may allow use of nonideal lungs and expansion of the donor
pool.
PGD is the result of the cumulative effects of allograft
injury that occur secondary to donor brain death, organ harvest,
cold preservation, and reperfusion. Effective control of allo-
graft function must address each of these distinct processes.
The technique of modified reperfusion focuses predominantly
on the issues of reperfusion. A comprehensive approach to the
management of PGD must include attention to donor manage-
ment, organ harvest, and preservation, in addition to reperfu-
sion. Furthermore, this technique is only a vehicle for control-
ling the reperfusion process. With greater understanding of
c and Cardiovascular Surgery ● Volume 131, Number 1 221
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reperfusate is likely to, and should, change.
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Discussion
Dr Wickii T. Vigneswaran (Maywood, Ill). I would like to
congratulate Dr Schnickel and his colleagues for an elegant pre-
sentation of their report.
A severe form of pulmonary graft dysfunction remains a sig-
nificant cause of morbidity and mortality following lung transplan-
tation. Increasing knowledge of the mechanism of primary graft
failure has led to improvements in donor management, organ preser-
vation, and recipient management in the perioperative period. Further
measures to reduce early graft dysfunction are important to im-
prove outcomes. The authors have demonstrated that reperfusion
of the lung allograft with a modified reperfusate following single
or bilateral lung transplantation is feasible and safe.
However, I have some concerns about your conclusion that the
technique of modified reperfusion is associated with a low inci-
dence of severe pulmonary graft dysfunction and favorable short-
term outcomes. This is an uncontrolled retrospective review. Fur-
thermore, the cohort of patients in this report is heterogeneous.
Two different techniques were used for preservation of the
donor. Forty-two percent of the patients underwent a single-lung
transplantation. In 63% of the patients, a CPB was used for the
transplantation. In single-lung transplant, the remaining native
lung can influence the PaO2/FIO2 ratio. The conduct of CPB during
lung transplantation can modify the inflammatory response. I would
like to ask you whether you used aprotinin, a potent anti-inflammatory
agent, or leukocyte depletion of the prime or in the cardiopulmonary
circuit during your operation. I would also like to know whether any
subset of your patients received nitric oxide before reperfusion.
Dr Schnickel. Thank you for your comments.
Regarding aprotinin, yes, we do use aprotinin on those patients
who undergo transplant on bypass. In regards to the nitric oxide,
we currently use nitric oxide only when indicated for either ele-
vated pulmonary artery pressures or for poor oxygenation. We
don’t routinely use it as part of our protocol.
Dr Vigneswaran. So there was a subset of patient who re-
ceived nitric oxide but after the reperfusion of the graft?
Dr Schnickel. Correct.
Dr Vigneswaran. The incidence of primary graft dysfunction
in the literature varies from single digits to over 30%. One of the
major setbacks of evaluating the results in the literature is the
absence of uniformity in the definition of primary graft dysfunc-
tion. The most frequently used definition is a PaO2/FIO2 ratio of less
than 200 with diffuse infiltrates in the chest radiograph. The
working group of the International Society for Heart and Lung
Transplantation proposed a classification system to make it uni-
form, and the grade 3, which is to denote the severe form of
pulmonary graft dysfunction, was defined as a PaO /FIO ratio less2 2
than 200 with diffuse infiltrates in the chest radiograph. The
ary 2006
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the threshold high, the observed incidence of primary graft dys-
function can be lowered artificially. In your table, the PaO2/FIO2
ratio at 1 hour was 187  112.9. I would like you to comment: is
the incidence of primary graft dysfunction lower because of the
definition you used and how you analyzed the data?
Dr Schnickel. The ISHLT [International Society for Heart and
Lung Transplantation] working group, as you said, has referenced
a PGD grade 3 as less than 200 with chest radiograph infiltrates.
When we first wrote this and when we first looked at our data, the
ISHLT working group hadn’t yet published their abstract, and they
just recently presented it as an abstract at the ISHLT. So for that
reason and for the reason that our previous work and the work of
others has used a ratio of 150 or less, we chose that. In our future
work, we definitely agree that we should all standardize our defini-
tions of PGD. We did in fact go back and look at our incidence, and
if it’s classified as under 200, the PaO2/FIO2 ratio, our incidence is
3% rather than 2%.
Dr Vigneswaran. If your analysis shows such an outcome, it is
very good.
Severe primary graft dysfunction is associated with a longer
intubation time, length of stay in the ICU, and longer length of
hospital stay following lung transplantation. I hope I am not too
naive in saying that the reverse should be true; if the primary graft
dysfunction is lower, you should have a shorter length of intuba-
tion, ICU stay, and hospital length of stay.
Lung transplantation is continuously evolving, and there are
always measures taken to improve the technique and conduct of
the operation, so any meaningful comparisons can only be made to
contemporary reports. The University Healthcare Consortium re-
porting data during the same years as yours for similar cohorts of
patients from participating centers estimated that the hospital
length of stay should be about 10 to 11 days following lung
transplantation. We reported our experience from the Loyola Uni-
versity Medical Center last year at the ACCP [American College
of Chest Physicians] meeting of 117 patients during the same
period as yours. The groups are very comparable for etiology,
donor-preservation techniques, and types of transplantation. Only
15% of our patients required CPB, and these were mainly for
severe pulmonary hypertension, either primary or secondary. The
reperfusion of the allograft was done in the traditional way, by
gradually unclamping the pulmonary artery. A critical pathway
The Journal of Thoraciguided our postoperative management. The early mortality was
5.8% in our cohort, but the striking difference was that in our
cohort, the median length of intubation was 16 hours and the
median hospital length of stay was 7 days—almost half what you
have reported. Could you comment on the longer intubation time
and the prolonged hospital length of stay compared with what was
expected in this cohort? Were there any late-onset pulmonary or
other medical or nonmedical reasons for this observation?
Dr Schnickel. Loyola is known as an outstanding transplant
center in the area of lung transplantation. I applaud your results.
I don’t have any explanation for why your intubation time is
much better than ours. I mean obviously we did look at days rather
than hours, so that may account for some of the difference, but we
don’t have a protocol per se about the exact time of extubation. I
really don’t have an explanation why your intubation time is
shorter than ours. In terms of the CPB, that’s part of our routine
procedure for all double-lung transplants. It makes the modified
reperfusion easier to instill, and it’s just part of our routine. We
have found that very effective.
Dr Bryan F. Meyers (St Louis, Mo). You had great clinical
results, but I also share concerns that it might not have been
achieved by reduction of ischemia-reperfusion injury by your
techniques. You reported your PaO2/FIO2 ratio at 6 hours at 252,
plus or minus 120. Normally you would expect about 60% of the
scores to fall between 1 standard deviation above and 1 below the
mean. So I would expect two thirds of your scores to be between
130 and 375. It seems like there would be room for about 15% or
18% of the scores to be below 130. When I look at Dahlberg’s
presentation in the Journal of Heart and Lung Transplantation in
2004, they reported a median in the 300 to 400 range. When we
checked our own results at Washington University for 700 trans-
plants, the mean PaO2/FIO2 ratio at time 0 was 319 and at time 24
hours was 318, yet last year we reported an ischemia-reperfusion
injury rate of about 22% using the same threshold as you. I think
there is something that doesn’t quite add up. It might be your use
of the 48-hour time mark, or it might be your inclusion of the
radiograph, but it seems like your results are similar to other
reported groups, and maybe not even as good if you look at the
PaO2/FIO2 ratio. However, your clinical results are excellent, and I
commend you on the report.Dr Schnickel. Thank you.
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